Donna Skerrett, M.D., M.S.

As Mesoblast’s chief medical officer, Dr. Skerrett oversees the human clinical trial programs. She has been involved in stem cell procurement, manipulation, and transplantation for nearly 20 years. Her areas of expertise include conventional transfusion medicine, immunohematology, apheresis, histocompatibility testing and stem cell apheresis and processing, and novel regenerative medicine translational therapy.

Dr. Skerrett has worked on the design and execution of conventional and innovative stem cell therapies in hematopoietic recovery, cardiac repair, skeletal repair, cartilage preservation, angiogenesis stabilization in eye disease and most recently, inflammatory and metabolic diseases. Dr. Skerrett was director of the Stem Cell Facilities at Weill-Cornell Medical Center in New York and previously served as associate director of Transfusion Medicine at Columbia University’s New York-Presbyterian Hospital. She is an advisor to the New York State Department of Health on the progenitor cell committee and has been chair of the Governor’s Council on Blood and Transfusion Services. Dr. Skerrett joined Mesoblast in 2004.

Comments are closed.